137 related articles for article (PubMed ID: 20564918)
1. [Effect of mucolytic therapy on the production of reactive oxygen species in the blood of patients with an exacerbation of chronic obstructive pulmonary disease].
Farkhutdinov UR; Farkhutdinov RR; Petriakov VV; Farkhutdinov ShU; Mirkhaĭdarov AM
Ter Arkh; 2010; 82(3):29-32. PubMed ID: 20564918
[TBL] [Abstract][Full Text] [Related]
2. [The effect of inhaled ambroxol treatment on clinical symptoms and chosen parameters of ventilation in patients with exacerbation of chronic obstructive pulmonary disease patients].
Jahnz-Rózyk K; Kucharczyk A; Chciałowski A; Płusa T
Pol Merkur Lekarski; 2001 Sep; 11(63):239-43. PubMed ID: 11761819
[TBL] [Abstract][Full Text] [Related]
3. [Antioxidative features of ambroxol--usefulness in COPD].
Nowak D
Pneumonol Alergol Pol; 2001; 69(9-10):590-3. PubMed ID: 11928667
[No Abstract] [Full Text] [Related]
4. Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial).
Malerba M; Ponticiello A; Radaeli A; Bensi G; Grassi V
Pulm Pharmacol Ther; 2004; 17(1):27-34. PubMed ID: 14643168
[TBL] [Abstract][Full Text] [Related]
5. Exacerbations of chronic obstructive pulmonary disease.
Wedzicha JA; Donaldson GC
Respir Care; 2003 Dec; 48(12):1204-13; discussion 1213-5. PubMed ID: 14651761
[TBL] [Abstract][Full Text] [Related]
6. [Intravascular laser irradiation of blood in the treatment of patients with bronchial asthma].
Farkhutdinov UR
Ter Arkh; 2007; 79(3):44-8. PubMed ID: 17526196
[TBL] [Abstract][Full Text] [Related]
7. Influence of mucolytic therapy on respiratory mechanics in patients with chronic obstructive pulmonary disease.
Schreiber J; Bohnsteen B; Rosahl W
Eur J Med Res; 2002 Mar; 7(3):98-102. PubMed ID: 11953279
[TBL] [Abstract][Full Text] [Related]
8. Plant-based formulation in the management of chronic obstructive pulmonary disease: a randomized double-blind study.
Murali PM; Rajasekaran S; Paramesh P; Krishnarajasekar OR; Vasudevan S; Nalini K; Lakshmisubramanian S; Deivanayagam CN
Respir Med; 2006 Jan; 100(1):39-45. PubMed ID: 15905081
[TBL] [Abstract][Full Text] [Related]
9. [The combined drug ascoril in the treatment of patients with chronic obstructive pulmonary disease concurrent with coronary heart disease].
Grigor'eva NIu; Kuznetsov AN; Koroleva TV; Koroleva ME
Ter Arkh; 2013; 85(8):91-4. PubMed ID: 24137971
[TBL] [Abstract][Full Text] [Related]
10. Oral neltenexine in patients with obstructive airways diseases: an open, randomised, controlled comparison versus sobrerol.
Fadda G
Minerva Med; 2001 Aug; 92(4):269-75. PubMed ID: 11535970
[TBL] [Abstract][Full Text] [Related]
11. [Mucolytics in acute and chronic respiratory tract disorders. II. Uses for treatment and antioxidant properties].
Kupczyk M; Kuna P
Pol Merkur Lekarski; 2002 Mar; 12(69):248-52. PubMed ID: 12053601
[TBL] [Abstract][Full Text] [Related]
12. [Medical maintenance treatment of chronic obstructive pulmonary disease (COPD)].
Kerstjens HA; Postma DS
Ned Tijdschr Geneeskd; 2002 Aug; 146(35):1631-5. PubMed ID: 12233157
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of mild exacerbations of chronic obstructive pulmonary disease].
Kliachkina IL; Dmitriev IuK
Klin Med (Mosk); 2012; 90(3):69-73. PubMed ID: 22690572
[TBL] [Abstract][Full Text] [Related]
14. Association between incidence of acute exacerbation and medication therapy in patients with COPD.
Suh DC; Lau H; La HO; Choi IS; Geba GP
Curr Med Res Opin; 2010 Feb; 26(2):297-306. PubMed ID: 19961283
[TBL] [Abstract][Full Text] [Related]
15. [Chronic obstructive pulmonary disease exacerbation. Do we use all possibilities of outpatient therapy?].
Leshchenko IV
Ter Arkh; 2013; 85(10):83-7. PubMed ID: 24437224
[TBL] [Abstract][Full Text] [Related]
16. Neltenexine tablets in smoking and non-smoking patients with COPD. A double-blind, randomised, controlled study versus placebo.
Cattaneo C
Minerva Med; 2001 Aug; 92(4):277-84. PubMed ID: 11535971
[TBL] [Abstract][Full Text] [Related]
17. Antiinflammatory properties of ambroxol.
Beeh KM; Beier J; Esperester A; Paul LD
Eur J Med Res; 2008 Dec; 13(12):557-62. PubMed ID: 19073395
[TBL] [Abstract][Full Text] [Related]
18. [Inhalational antibacterial therapy for an exacerbation of chronic obstructive pulmonary disease].
Nefedova MN; Shmelev EI
Probl Tuberk Bolezn Legk; 2008; (8):8-11. PubMed ID: 18822473
[TBL] [Abstract][Full Text] [Related]
19. [Ambroxol].
Akkoca Yildiz O
Tuberk Toraks; 2006; 54 Suppl 1():3-14. PubMed ID: 17089236
[No Abstract] [Full Text] [Related]
20. Short-term perioperative treatment with ambroxol reduces pulmonary complications and hospital costs after pulmonary lobectomy: a randomized trial.
Refai M; Brunelli A; Xiumé F; Salati M; Sciarra V; Socci L; Di Nunzio L; Sabbatini A
Eur J Cardiothorac Surg; 2009 Mar; 35(3):469-73. PubMed ID: 19144532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
